Clinical Trial Update: Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and pharmacokinetics of olaratumab in Japanese participants with solid tumors. The study is completed with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Olaratumab (olaratumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Malignancy, Metastasis | Phase 1 | Status: COMPLETED | Results posted: 2017-04-14